Business
Sisram Medical Partners with Sinmait Medical Technology to Build Next-Generation Manufacturing and Innovation Hub in China
Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced that its wholly-owned subsidiary, Sisram Medical China (Tianjin) Ltd., has entered into a memorandum of understanding ("MOU") with Sinmait Medical Technology (Beijing) Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Thi
About this update from Sisram Medical Ltd.
[{"type":"text","content":"HONG KONG, Jan. 21, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced that its wholly-owned subsidiary, Sisram Medical China (Tianjin) Ltd., has entered into a memorandum of understanding ("MOU") with Sinmait Medical Technology (Beijing) Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. This MOU establishes a framework for cooperation aimed at enhancing localization efforts in China.","length":676,"tagName":"p"},{"type":"text","content":"This partnership is poised to accelerate Sisram's strategic implementation and business expansion in the Chinese market, strengthen the resilience of its global supply chain, and solidify the Company's position as a leader in innovation and market presence in medical aesthetics, both locally and globally.","length":314,"tagName":"p"},{"type":"text","content":"By deepening its partnership with Fosun Pharma, Sisram will leverage Sinmait's advanced production capabilities and local expertise to establish a robust manufacturing hub in China, initially focused on localized production of Energy-Based Devices (EBD) and setting the stage for expansion into a broader product portfolio.","length":327,"tagName":"p"},{"type":"text","content":"The new facility will cater to domestic demand and serve as a strategic center for the APAC region, addressing the growing need for scalable production, sophisticated logistics, and advanced research and development.","length":216,"tagName":"p"},{"type":"text","content":""This collaboration with Fosun Pharma elevates Sisram's localization strategy in China to a new level," said Mr. Lior Dayan, Chairman and Executive Director of Sisram Medical. "The core significance of this partnership lies in building a comprehensive, resilient, and competitive localized ecosystem. It represents a key milestone in our vision of 'In China, for Global,' setting the foundation for scalable, sustainable growth and long-term value creation."","length":490,"tagName":"p"},{"type":"text","content":"As combined therapies gain traction in China's medical aestheti...